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Abstract
Functionalised cyclodextrin molecules assemble into a wide variety of superstructures in solution, 
which are of interest for drug delivery and other nanomaterial and biomaterial applications. Here we 
use a combined simulation and experimental approach to probe the co-assembly of siRNA and 
cationic cyclodextrin (c-CD) derivatives into a highly stable gene delivery nanostructure. The c-CD 
form supramolecular structures via interdigitation of their aliphatic tails, analogous to the formation 
of lipid bilayers and micelles. The native conformation of siRNA is preserved by the encapsulating 
c-CD superstructure in an extensive hydrogen bonding network between the positively charged 
sidearms of c-CD and the negatively charged siRNA backbone. The stability of the complexation is 
confirmed using isothermal titration calorimetry, and the experimental/simulation co-design 
methodology opens new avenues for creation of highly-engineerable gene delivery vectors. 
Introduction 
Gene silencing via RNA interference (RNAi) using short (∼20-25 nucleotides) double-stranded RNA 
(siRNA)1-14, provides the opportunity to design a new generation of therapeutics capable of treating 
a wide range of diseases including those with high unmet needs such as brain cancers and 
neurodegenerative disorders12, 15-17. Following parenteral administration, nucleases in the blood and 
at the cellular level degrade siRNA18, which compromises the effectiveness of the nucleic acid based 
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2therapeutics16-17. However, the small size and relative simplicity of siRNA (compared to complete 
RNA or DNA19) provides opportunities for targeting of the biomolecule by nanoparticle-based 
delivery3-4, 6-8, 10, 20-23. Both organic (lipid-based8, 12 or otherwise) and inorganic carriers12, 18-19, 24-25 
increase the permeability of the cellular membrane and deliver siRNA to the target site. While brain 
delivery remains a major challenge, knowledge of the self-assembly properties of a gene delivery 
vector and of its complexation with nucleic acids may enhance understanding of its interactions with 
living cells. In particular, cationic lipid-based nanovectors form tightly-bound complexes with siRNA 
which translocate through the phospholipid bilayer. Although some progress has been made, the 
major barrier to clinical translation of this method is the lack of nontoxic, effective delivery systems 
that can be manufactured to consistent quality, ensuring delivery to the diseased site and achieving 
the required duration of activity26. 
To date, the delivery problem has been tackled using viral and non-viral approaches. Viral 
technologies for nucleic acid delivery are remarkably effective and have made significant progress, 
with several FDA approved products including CAR-T cell therapy (Novartis) for treatment of 
paediatric relapsed/refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL), and Luxturna™ 
(voretigene neparvovec) for treatment of vision loss due to confirmed biallelic RPE65-mediated 
inherited retinal dystrophies (Spark Therapeutics). In contrast, development of non-viral approaches 
has lagged behind27. However the recent design and synthesis of biocompatible materials capable of 
producing nano-complexes with nucleic acids has resulted in more promising clinical data and it is 
anticipated at time of writing in December 2018 that the first non-viral RNAi therapeutic using a 
lipid-based nanoparticle formulation for liver disease (www.alnylam.com) will reach the market in 
the coming year.
Among a variety of nanocarriers, the potential of cyclodextrin (CD) molecules19, 21 as 
promising delivery platforms for therapeutic oligonucleotides has been well established28. 
Cyclodextrins are a biocompatible family of cyclic oligosaccharides with hydrophilic primary and 
secondary faces and a hydrophobic cavity. The presence of hydroxyl groups on the ring structure 
allows modifications with different functional groups, giving rise to a library of compounds including 
amphiphilic, cationic, anionic, PEGylated and targeted CDs28-29. Co-formulation of selected CD 
derivatives has resulted in the design of ‘bespoke’ nanoparticles loaded with nucleic acid for targeting 
to specific disease sites30-32. These modified CDs have successfully delivered both plasmid pDNA33-
34 and siRNA by enhancing cellular uptake, promoting endosomal release resulting in significant 
levels of transfection and gene knockdown26-27. For example, a 70nm cyclodextrin-based nanoparticle 
can package ∼2000 siRNA molecules in a 20:1 ratio for targeted delivery7, 10. Proof of concept has 
also been shown in vivo in animal models of prostate cancer20, Huntington’s disease35 and 
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3inflammatory bowel disease (IBD)36. More recently, antibody targeted CD nanoparticles have shown 
gene silencing and therapeutic efficacy in blood from adult acute myeloid leukaemia AML patients37. 
Preliminary toxicity studies in vitro and in vivo have confirmed the safety of these CDs38.
Initial characterisation studies have elucidated the physicochemical properties and the 
molecular alignment in CD-based nanocomplexes. Routinely the size, charge and shape of NPs, 
essential parameters known to influence therapeutic activity, are monitored using techniques 
including dynamic light scattering (DLS), zeta potential measurements, electron and atomic force 
microscopy. For example, the self-assembly properties of two cationic amphiphilic cyclodextrins 
(C16 vs. C12 alkylthiol lipid chain lengths) following complexation with DNA have been investigated 
using small angle X-ray scattering (SAXS) to probe the structure of the complexes and locate DNA 
within them39. The cyclodextrin with the longer C16 lipid chain formed multi-lamellar nano-
assemblies with DNA bound between the two polar layers of the CD protonated amino groups in 
alternation with the lipid bilayers. In contrast, the cyclodextrin with the shorter lipid chain forms 
micelles, which aggregate into clusters following electrostatic interaction with DNA. These results 
indicate that the hydrophobic-hydrophilic balance between the two faces of cationic amphiphilic 
cyclodextrins modulated the structures of complexes formed with nucleic acids. Finally, circular 
dichroism has been used to monitor the conformational changes of DNA and RNA in cyclodextrin 
complexes40. Although siRNA was more susceptible than DNA to conformational changes, 
complexation with CDs had a stabilizing effect that maintained the A-form secondary structure 
essential for gene silencing. In addition, factors such as temperature and pH were shown to influence 
the conformation of the nucleic acids, which may be relevant considerations for processing and 
manufacture.
In summary, the supramolecular structure of RNA-carrier complexes has been shown to 
influence therapeutic performance and stability during manufacture, storage and following exposure 
to biological fluids. Non-viral nanocomplexes are likely to be multi-component formulations 
necessary to overcome the complex in vivo barriers to delivery. Therefore, it is essential to 
characterize in as much detail as possible the nature of interactions with the encapsulated nucleic 
acids. The aim of this work is to use molecular dynamics computer simulations in tandem with 
isothermal titration calorimetry (ITC) to advance our knowledge of CD-nucleic acid interactions41-42, 
to help toward identifying the optimum design features required to maximize performance and 
minimize toxicity.
Methods
Molecular dynamics computer simulations: In this study, we used state of the art molecular dynamics 
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4(MD) computer simulations to model the dynamic encapsulation of siRNA via templated self-
assembly of β-cyclodextrin derivatives on the siRNA surface. 21-base pair siRNA molecular models 
were built using A-DNA PDB structures as templates (5IYE43, 5MVT, 5MVQ44, 5OKL45, 3V9D46), 
and the uracil nucleobases were modified to 2’-o-methyluridine at 4 positions. Click-propyl-amine 
cationic β-cyclodextrin models were generated from published molecular structures28, 30, 47. Each 
complex was solvated in TIP3P48 water in a cubic box of edge length 18 nm and any net charge was 
neutralized by adding background Na+ and Cl- ions. All studies were carried out employing periodic 
boundary conditions with Particle Mesh Ewald method49 to treat long-range electrostatics. High 
frequency bonds to hydrogen were constrained using the LINCS algorithm50 which allowed the use 
of a two femtosecond (2 fs) time step to integrate the equations of motion. The simulation cells were 
equilibrated and thermalized51-52 over 10 ns of molecular dynamics to obtain a stable constant 
pressure-temperature (NPT) ensemble at 1 atm and 300K. Force field parameters for cationic β-
cyclodextrin (CD)51-52 were derived using the Charmm generalized force field (CgenFF)53 for small 
molecule parameterization. This modified version of the Charmm36 force field54-57 was used to 
simulate the solvated siRNA-CD complexes with the Gromacs MD code version 2016-beta258-59. We 
first simulated the formation of a stable complex between siRNA and single β-cyclodextrin and 
cationic β-cyclodextrin (cCD) molecules and then modelled the interaction of siRNA with multiple 
β-cyclodextrins (native CD and cCD) at mass ratio of up to 1:10.
Isothermal titration calorimetry experiments: All experimental measurements were carried out using 
the MICROCAL™ PEAQ-ITC (Malvern Panalytical Ltd., United Kingdom). A solution of 100 µM 
of the Click propyl-amine CD was loaded into the syringe and the nucleic acid (siRNA at 10 µM) 
deposited in the sample cell, in both cases at pH 6. Trifluoroacetate was also present as a counter-ion. 
The reference cell was loaded with ultra-pure RNAse-free water. After a 60-second delay and an 
initial injection of 0.4 µL (to negate diffusion effects) a typical experiment involved a series of 19 
injections of 2 µL of the titrant solution into the cell. The sample cell was stirred at 750 rpm 
throughout the experiment and the experimental temperature was maintained at 25°C. The 
feedback/gain mode was set to low. The area under the peak of the resulting heat profile was 
integrated, normalized by the concentrations, and plotted against the molar ratio of ligand to protein 
using MicroCal PEAQ-ITC analysis software. The resulting binding isotherms were fitted by 
nonlinear regression using a one set of sites model to yield the stoichiometry of the interaction (n), 
the equilibrium dissociation constant (KD), and the change in enthalpy (ΔH). The Gibbs free energy 
change (ΔG) was calculated from ΔG = -RT lnKD and the entropy (ΔS) from ΔG = ΔH – T ΔS.
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5Results and Discussion
The dynamical self-assembly behaviour of β-cyclodextrin (CD) derivatives around siRNA was 
investigated using classical MD simulations in water at ambient temperature (300K). The data 
confirms the structural stability of siRNA under physiological conditions and shows that siRNA 
templates its encapsulation via the self-assembly of cationic amphiphilic β-cyclodextrin (cCD) 
molecules into a cloaking bilayer. Our computed high complex stability is confirmed using 
experimental ITC measurements.
Computed structure, dynamics and energetics of siRNA/CD and siRNA/cCD complexes: For a better 
understanding of the complexation process, we performed multiple unbiased MD simulations of 
siRNA/CD and siRNA/cCD complexation, starting from completely unbound conformations with 
siRNA and the host molecules well separated in water. The simulations were performed at ambient 
temperature, and structures were initially sampled for 200 ns for single CD complexes and multi-CD 
complexation in a siRNA:CD mass ratio of 1:10 (1:120 for CD and 1:39 molecules for the cCD). The 
simulations where extended up to 1 s when necessary. In addition, control simulations (200 ns each) 
of siRNA alone in water and also CD (native and cCD) dimerization alone in water were performed, 
to compare with the calculated CD/siRNA complexes. 
The simulations of siRNA alone and complexed to a single native CD or cCD unit confirm 
that siRNA is stable in water at ambient conditions, as deduced from computed structural parameters 
including Radius of Gyration (Rg), Root Mean Square Deviation (RMSD), and Root Mean Square 
Fluctuations (RMSF). Computed Rg values highlight the compactness of siRNA, averaging 19.0 ± 
0.2 nm for all, which is close to the known B-DNA Rg value. The RMSD of uncomplexed siRNA 
(Figure 1A) ranges between ~0.1 and 0.6 nm. The modest increase in RMSD of siRNA with 
complexed CD suggests, in agreement with similar studies60, that the structure of siRNA is not 
significantly altered by CD.  This is confirmed by the scan of RMSF values across the 42-base RNA 
molecule (Figure 1B) which shows that molecular fluctuation in siRNA is localised at the ends of the 
duplex. Terminal base-fraying is inhibited in the siRNA/cCD complex because the cCD molecule 
targets one of the terminal base-pairs. Such nanovector-mediated preservation of the native siRNA 
molecular structure is a potentially useful design principle in that it may increase the ability of siRNA 
to perform its designated function in vivo. Having confirmed the stability of siRNA in our model, we 
present below details of the molecular mechanism of self-assembly of siRNA nanovectors from cCD 
molecules. 
The binding complex between siRNA and unfunctionalised CD(1:1) shows very specific 
interaction modes of CD with the major groove of siRNA (Figure 2). It shows two primary binding 
modes as previously shown by Manzanares et al.61 The first can be described as perpendicular 
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6insertion of CD into the major groove, sandwiched between two strands (Figure 2A). The second 
binding mode is laterally aligned full CD interaction with the siRNA backbone (Figure 2B). The first 
binding mode persists for ∼70ns simulation time before switching to the second binding mode. The 
insertion of CD in the major groove modulates the structural dynamics of siRNA with a minor 
localized widening of the major groove (Figure 2C), hence comparatively higher fluctuation (Figure 
1) in RMSD (from ~40-90ns) and RMSF (4-terminal base pairs) data.
Figure 1 A comparison of the computed dynamics of siRNA (Root Mean Square Deviation [A] and 
Root Mean Square Fluctuation [B]) in solution and complexed with native CD and cationic cCD 
(1:1). The molecular structure of c-CD, heptakis[2-O-(N-(3′′-aminopropyl)-1′H-triazole-4′-yl-
methyl)-6-dodecylthio]-β-cyclodextrin trifluoroacetat (Click-CD, MW: 4191 g/mol) is shown in the 
inset of panel B. Computed average siRNA conformations are shown on the right.
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7Upon introducing a second CD, CD−CD dimerization competes with CD−siRNA binding and 
so only transient, non-specific CD−RNA binding modes are observed (Figure 2D-F). At the higher 
CD concentration, siRNA is mostly a simple solvated structure with very little deviation from the 
starting equilibrated conformation. When complexed to siRNA, CD forms on average two hydrogen 
bonds per molecule which gives small decreases in base-pair hydrogen bond populations. 
Figure 2 Computed preferred binding modes of unmodified CD to siRNA(1:1 [A-C] and 1:2 [D-F]).
By contrast, siRNA is more stable when complexed to cCD. The cCD molecule interacts with 
the siRNA backbone via its cationic amino groups (Figure 3). cCD walks along the backbone and 
anchors tightly on the terminal base-pair at one end of siRNA, where it remains for the duration of 
the simulation. Upon insertion of a second cCD, similar interaction occurs with the backbone of 
siRNA with no dimerization between the charged cCD molecules. The second cCD molecule binds 
to the middle of the siRNA, splaying across the major groove. The end-bound cCD molecule forms 
on average five H-bonds to siRNA and the second CD forms ten H-bonds. These results are in good 
agreements with simulations performed on chitosans which show that the encapsulation of DNA 
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8strands depends on both the charge of the functionalized group and on the number of H-bonds a vector 
can form with DNA/siRNA62.
Figure 3 Computed preferred binding modes of cCD to siRNA(1:1[A-C] and 1:2[D-F]).
Computed self-assembly on CD-based nano-vectors around siRNA: On increasing the 
siRNA/CD mass ratio to 10 (1:120 molecules), the native CD molecules formed mostly native dimer 
configurations with a small population also of tetramers. These higher order CD structures interacted 
with siRNA but without any specific assembly of the units on siRNA surface during the 0.5 s 
simulations. The interactions among siRNA and CD do not significantly alter the siRNA (Figure 
4A,B), as the number of H-bonds oscillates between 5 and 10 per CD (Error! Reference source not 
found.C) to give very short lived and non-specific complexation (Figure 4D). One large cluster of 
loosely-bound CD dimers persists for few hundred nanoseconds at one terminus during the simulation, 
but still no specific pattern of assembly emerges from analysis of the CD-CD and CD-siRNA contacts, 
indicating that at high concentration unmodified CD simply aggregates non-specifically on siRNA. 
The assembly reduces the solvent accessible surface area (SASA) of siRNA and ∼80 H-bonds to 
water are lost as the siRNA to sugar H-bonding increases 6-fold (compared with native CD) to make 
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9a tight, specific electrostatically-bound complex (Figure 4C,D). The partial or total coverage of 
siRNA by cationic vectors including cylodextrins, chitosans, PGA, PMAL and PAMAM, with 
corresponding reduction of solvent accessibility to the nucleotides, has been observed in various 
experimental and modelling studies and is essential to preserve the stability of the siRNA and allow 
it to cross the cell lipid membrane.60-66
Figure 4 Comparison of the computed properties of siRNA/CD and siRNA/cCD complexes 
assembled at a mass ratio of 10. [A] RMSD, [B] RMSF per residue, [C] hydrogen bonding between 
siRNA and CD/cCD, and [D] radial distribution of CD/cCD from the siRNA center of mass. 
By contrast, cCD dimers formed in the very early stages of the simulation condense into 
multimeric units on the surface of siRNA (Figure 5). The cCD molecules use their cationic termini 
to anchor to the negatively charged nucleic acid bases and form multimeric supramolecular structures 
along the backbone. The cationic groups dangle in the major groove of the siRNA, which generates 
a pull that causes fraying of one terminal base-pair (residues 21 and 22) at one end of siRNA, as 
reflected in the rise in RMSF (Error! Reference source not found.B). This is the only change in the 
physical and structural parameters of siRNA as the encapsulating cCD superstructure assembles 
around it. The cCD molecules form dimers and then these dimers associate into larger assemblies, 
showing behaviour analogous to biological lipids due to the cationic modification at one face of the 
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10
CD ring and the long hydrophobic aliphatic chains on the other face. The cCD molecules stack 
together via interdigitation of the aliphatic chains and the charged head groups at each end anchor 
either to the negatively charged nucleic acid backbone or face out into solvent. This type of 
association into bilayer patches creates a hydrophobic core and positively charged head groups create 
the external boundaries of the bilayer, mimicking natural lipid bio-membranes. This type of multi-
lamellar nano-assembly was previously observed in the case of DNA complexed with our modified 
CDs39. The largest assembly observed during the simulations comprised a hexamer of six cCD 
molecules on the surface of nucleic acid, while three other secondary assemblies also form on the 
surface of the nucleic acid backbone containing 4-6 cCD molecules at a time. 
Figure 5 Representative computed self-assembled multimeric units of 39 cCD molecules around 
siRNA. Panel (A) shows how the originally randomly distributed cCD converge towards the siRNA. 
Panel (B) illustrates formation of cCD clusters at the three main interaction points of the siRNA, the 
two ends and in the middle around a major groove. (C) Assembly of a 6 cCD molecule bilayer 
structure at one end of siRNA. Dashed yellow lines mark the CD ring alignment. (D) Formation of a 
6 cCD molecule bilayer in water. The cationic sidearms of cCD are coloured blue, the central sugar 
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11
rings are coloured white and the interdigitating aliphatic chains are coloured red and green to 
distinguish the first and second layer in the assembly.
The free cCD molecules in the solvent are rarely in a single unit conformation, but instead 
exist in dimer, trimer, tetramer and occasionally pentameric/hexameric assemblies. The rapid 
assembly of cCD on the surface of siRNA suggests that these modified CDs have biological lipid-
like self-assembly behaviour, encapsulating siRNA in a stable electrostatically bound carrier which 
does not significantly affect the overall average structural properties of the siRNA molecule, as 
required for the design of nano-vectors for targeted delivery of nucleic acid and other small (charged, 
hydrophilic) drug molecules. The maintenance of the structural intergrity of siRNA in the cCD 
complex is consistent with previously published circular dichroism results40. The H-bond profiles of 
siRNA/CD and siRNA/cCD (Error! Reference source not found.C) clarifies the improved 
assembly behaviour obtainable with cCD, as the cCD molecules assemble into bi-layered structures 
with 6-fold increase (compared with native CD) in electrostatic interactions with siRNA. The 
pronounced peak in the computed radial distribution function for cCD (Error! Reference source not 
found.D) indicates specific assembly of ordered cCD structures on the surface of siRNA, while 
unmodified CD shows a broader, less featured distribution reflecting weaker, less specific, shorter-
lived interactions with siRNA. 
A more detailed analysis of the assemblies is shown in Error! Reference source not found.. 
Aggregation proceeds by growing the average cluster sizes (Fig. 6A) while reducing the overall 
number of clusters.  Evidence of siRNA-templated assembly is provided for the three aggregates that 
make electrostatic contact with the siRNA surface (Fig. 6B) as they account for most of the assemblies 
of four or more cCD molecules. These aggregates show a tendency to coalesce further eventually 
forming a bilayer around siRNA. The experimentally-validated model for specific, electrostatic 
interaction between cCD and siRNA suggests a mechanism for templated assembly starting with the 
adhesion of few molecules at well-defined sites that serve as anchoring points for the self-assembly 
of a full lipid bilayer-like cloak around siRNA. The present microsecond trajectory captures the initial 
stages of this evolving structure with many cCD dimers and even tetramers still in suspension in the 
solvent. The largest assembly covers approximately 70% surface of the siRNA and uses 50% of 
available cCD molecules. Future work will involve extending to longer sampling times (using coarse 
grained models and metadynamics) and increasing concentrations of cCD, which may help further 
clarify the balance between cCD multimerisation and cCD−RNA electrostatic binding in creation of 
the full cCD siRNA delivery particle.
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12
Figure 6 Analysis of the cluster aggregates formed by cCD molecules in solution. Panel (A) shows 
the temporal evolution of number of clusters formed during 1 s of dynamics. Panel (B) shows the 
distribution of the number of cCD molecules per cluster: black represents all the aggregates, and blue, 
red and green represent the three aggregates coating siRNA. The inset shows the same information 
with the contributions of the three siRNA-binding clusters summed in the magenta histogram.
Experimental proof-of-concept testing of the predicted complexes: To investigate cCD complexation 
with a nucleic acid aqueous suspension of siRNA, we used ITC to quantify the heat released or 
absorbed during complexation. These measurements allowed us to confirm the type of interaction 
and estimate the energies produced during the binding process. In a typical ITC experiment, aliquots 
of a concentrated solution of cyclodextrins are added in a time-controlled manner to a cell containing 
the interacting molecule, which is maintained at constant temperature. During cyclodextrin addition, 
the two materials interact and the observed released heat is directly proportional to the amount of 
binding compound added with the solution aliquot. The molecular structure of c-CD is given in Figure 
1B above and the negative control non-silencing siRNA has sense strand sequence 5’-UUC UCC 
GAA CGU GUC ACG UdT dT-3 (siRNA Universal Negative Control (SIC001, Sigma, MW: 13,300 
g/mol). Parameters measured from ITC are given in Table 1 below (Figure 6).
Table 1 Thermodynamics of the guest:host interaction between siRNA (10 µM of 20-25 
nucleotide long double-strands) and c-CD (100 µM) in deionised water at 25.1 °C.
[Syringe: c-CD] 
[Sample Cell: siRNA]
Stoichiometry
±std. dev.
KD [µM]
±std. dev.
ΔH (kcal/mol)
±std.dev
ΔG 
(kcal/mol)
-TΔS 
(kcal/mol)
100: 10 µM-R1 0.53 ± 0.20 1.79 ± 0.97 -5.69 ± 1.30 -7.84 -2.15
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Figure 6 Typical ITC plot. Raw plot (A), integrated heat plot (B) of complex formation between 
Click-CD and siRNA solution at 10 µM. The dots depict the experimental results while the continuous 
line depicts the fitted curve. Signature plot (C), blue = Gibb’s free energy (G), green = enthalpy 
(,  red = entropic part (-TS).
 In aqueous solution, the interaction between c-CD and siRNA is exothermic and also 
spontaneous and is enthalpy driven with a low dissociation value. The magnitude of the released heat 
decreased progressively with each injection until the full complexation process was achieved. This is 
most likely related to the saturation process as c-CD assembles on siRNA (Fig. 7). The experimentally 
measured favourable enthalpy with small entropic contribution, confirms the prediction from the MD 
simulations that electrostatic interactions direct the siRNA encapsulation complexation. When CD 
binds to the siRNA, water molecules are displaced and move into the bulk water and this is 
entropically favorable. While electrostatic interactions direct the cCD−siRNA complexation, weaker 
van der Waals and hydrophobic interactions remain important for creation of the host superstructure 
via stacking of CD ring stacking and interdigitaiton of alkyl tails.
Conclusion
Click-CD molecules spontaneously form superstructures in solution which can assemble around 
Page 13 of 18
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14
siRNA to form a stable host that stabilises siRNA via electrostatic interactions. We employed large-
scale all-atom molecular dynamics simulations to track the assembly process and used isothermal 
titration calorimetry experiments to confirm the stability of the complexation between siRNA and the 
cCD superstructures. The negatively charged siRNA molecules serve as an ideal template around 
which the cationic cCD molecules rapidly assemble into stable multimers, which could provide a 
promising gene delivery vector. More generally, the computed structures further illustrate the lipid-
like behaviour of CD derivatives in solution and their capacity to form stable supra-structures, 
providing nanoscale molecular templates with highly controllable shape and size complexity.  The 
amphiphilic nature of the complex and the resulting bilayer formation will aid membrane permeability 
which should in turn enhance transfection activity.
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